Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.

Sallinen H, Janhonen S, Pölönen P, Niskanen H, Liu OH, Kivelä A, Hartikainen JM, Anttila M, Heinäniemi M, Ylä-Herttuala S, Kaikkonen MU.

BMC Cancer. 2019 Nov 19;19(1):1121. doi: 10.1186/s12885-019-6339-0.

2.

Dynamic contrast-enhanced perfusion parameters in ovarian cancer: Good accuracy in identifying high HIF-1α expression.

Lindgren A, Anttila M, Rautiainen S, Arponen O, Hämäläinen K, Könönen M, Vanninen R, Sallinen H.

PLoS One. 2019 Aug 22;14(8):e0221340. doi: 10.1371/journal.pone.0221340. eCollection 2019.

3.

Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.

Sopo M, Anttila M, Hämäläinen K, Kivelä A, Ylä-Herttuala S, Kosma VM, Keski-Nisula L, Sallinen H.

BMC Cancer. 2019 Jun 14;19(1):584. doi: 10.1186/s12885-019-5757-3.

4.

Effect of baseline hypocalcaemia on volume of intracerebral haemorrhage in patients presenting within 72 hours from symptom onset.

Sallinen H, Wu TY, Meretoja A, Putaala J, Tatlisumak T, Strbian D.

J Neurol Sci. 2019 Aug 15;403:24-29. doi: 10.1016/j.jns.2019.05.033. Epub 2019 May 30.

PMID:
31176195
5.

Prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian cancer.

Lindgren A, Anttila M, Arponen O, Rautiainen S, Könönen M, Vanninen R, Sallinen H.

Eur J Radiol. 2019 Jun;115:66-73. doi: 10.1016/j.ejrad.2019.03.023. Epub 2019 Mar 30.

PMID:
31084761
6.

Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors.

Ibanez L, Heitsch L, Dube U, Farias FHG, Budde J, Bergmann K, Davenport R, Bradley J, Carrera C, Kinnunen J, Sallinen H, Strbian D, Slowik A, Fernandez-Cadenas I, Montaner J, Lee JM, Cruchaga C.

Stroke. 2019 Jun;50(6):1339-1345. doi: 10.1161/STROKEAHA.118.023097. Epub 2019 May 14.

PMID:
31084338
7.

Quality of life and depression 3 months after intracerebral hemorrhage.

Sallinen H, Sairanen T, Strbian D.

Brain Behav. 2019 May;9(5):e01270. doi: 10.1002/brb3.1270. Epub 2019 Mar 24.

8.

Genetic and lifestyle risk factors for MRI-defined brain infarcts in a population-based setting.

Chauhan G, Adams HHH, Satizabal CL, Bis JC, Teumer A, Sargurupremraj M, Hofer E, Trompet S, Hilal S, Smith AV, Jian X, Malik R, Traylor M, Pulit SL, Amouyel P, Mazoyer B, Zhu YC, Kaffashian S, Schilling S, Beecham GW, Montine TJ, Schellenberg GD, Kjartansson O, Guðnason V, Knopman DS, Griswold ME, Windham BG, Gottesman RF, Mosley TH, Schmidt R, Saba Y, Schmidt H, Takeuchi F, Yamaguchi S, Nabika T, Kato N, Rajan KB, Aggarwal NT, De Jager PL, Evans DA, Psaty BM, Rotter JI, Rice K, Lopez OL, Liao J, Chen C, Cheng CY, Wong TY, Ikram MK, van der Lee SJ, Amin N, Chouraki V, DeStefano AL, Aparicio HJ, Romero JR, Maillard P, DeCarli C, Wardlaw JM, Hernández MDCV, Luciano M, Liewald D, Deary IJ, Starr JM, Bastin ME, Muñoz Maniega S, Slagboom PE, Beekman M, Deelen J, Uh HW, Lemmens R, Brodaty H, Wright MJ, Ames D, Boncoraglio GB, Hopewell JC, Beecham AH, Blanton SH, Wright CB, Sacco RL, Wen W, Thalamuthu A, Armstrong NJ, Chong E, Schofield PR, Kwok JB, van der Grond J, Stott DJ, Ford I, Jukema JW, Vernooij MW, Hofman A, Uitterlinden AG, van der Lugt A, Wittfeld K, Grabe HJ, Hosten N, von Sarnowski B, Völker U, Levi C, Jimenez-Conde J, Sharma P, Sudlow CLM, Rosand J, Woo D, Cole JW, Meschia JF, Slowik A, Thijs V, Lindgren A, Melander O, Grewal RP, Rundek T, Rexrode K, Rothwell PM, Arnett DK, Jern C, Johnson JA, Benavente OR, Wasssertheil-Smoller S, Lee JM, Wong Q, Mitchell BD, Rich SS, McArdle PF, Geerlings MI, van der Graaf Y, de Bakker PIW, Asselbergs FW, Srikanth V, Thomson R, McWhirter R, Moran C, Callisaya M, Phan T, Rutten-Jacobs LCA, Bevan S, Tzourio C, Mather KA, Sachdev PS, van Duijn CM, Worrall BB, Dichgans M, Kittner SJ, Markus HS, Ikram MA, Fornage M, Launer LJ, Seshadri S, Longstreth WT Jr, Debette S; Stroke Genetics Network (SiGN), the International Stroke Genetics Consortium (ISGC), METASTROKE, Alzheimer's Disease Genetics Consortium (ADGC), and the Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.

Neurology. 2019 Jan 16. pii: 10.1212/WNL.0000000000006851. doi: 10.1212/WNL.0000000000006851. [Epub ahead of print]

9.

Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage.

Tsivgoulis G, Wilson D, Katsanos AH, Sargento-Freitas J, Marques-Matos C, Azevedo E, Adachi T, von der Brelie C, Aizawa Y, Abe H, Tomita H, Okumura K, Hagii J, Seiffge DJ, Lioutas VA, Traenka C, Varelas P, Basir G, Krogias C, Purrucker JC, Sharma VK, Rizos T, Mikulik R, Sobowale OA, Barlinn K, Sallinen H, Goyal N, Yeh SJ, Karapanayiotides T, Wu TY, Vadikolias K, Ferrigno M, Hadjigeorgiou G, Houben R, Giannopoulos S, Schreuder FHBM, Chang JJ, Perry LA, Mehdorn M, Marto JP, Pinho J, Tanaka J, Boulanger M, Salman RA, Jäger HR, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A, Mitsias PD, Alexandrov AV, Ambler G, Werring DJ.

Ann Neurol. 2018 Nov;84(5):694-704. doi: 10.1002/ana.25342. Epub 2018 Oct 25.

PMID:
30255970
10.

Traumatic and spontaneous intracranial hemorrhage in atrial fibrillation patients on warfarin.

Lehtola H, Palomäki A, Mustonen P, Hartikainen P, Kiviniemi T, Sallinen H, Nuotio I, Ylitalo A, Airaksinen KEJ, Hartikainen J.

Neurol Clin Pract. 2018 Aug;8(4):311-317. doi: 10.1212/CPJ.0000000000000491.

11.

Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice.

Tuppurainen L, Sallinen H, Karvonen A, Valkonen E, Laakso H, Liimatainen T, Hytönen E, Hämäläinen K, Kosma VM, Anttila M, Ylä-Herttuala S.

Int J Gynecol Cancer. 2017 Jun;27(5):879-886. doi: 10.1097/IGC.0000000000000973.

PMID:
28498260
12.

Outcome of intracerebral hemorrhage associated with different oral anticoagulants.

Wilson D, Seiffge DJ, Traenka C, Basir G, Purrucker JC, Rizos T, Sobowale OA, Sallinen H, Yeh SJ, Wu TY, Ferrigno M, Houben R, Schreuder FHBM, Perry LA, Tanaka J, Boulanger M, Al-Shahi Salman R, Jäger HR, Ambler G, Shakeshaft C, Yakushiji Y, Choi PMC, Staals J, Cordonnier C, Jeng JS, Veltkamp R, Dowlatshahi D, Engelter ST, Parry-Jones AR, Meretoja A, Werring DJ; And the CROMIS-2 collaborators.

Neurology. 2017 May 2;88(18):1693-1700. doi: 10.1212/WNL.0000000000003886. Epub 2017 Apr 5. Erratum in: Neurology. 2018 Jun 5;90(23):1084.

13.

Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI.

Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivelä A, Mäkinen P, Härmä K, Hämäläinen K, Kosma VM, Ylä-Herttuala S, Vanninen R, Sallinen H.

Eur Radiol. 2017 Sep;27(9):4002-4012. doi: 10.1007/s00330-017-4786-z. Epub 2017 Mar 13.

14.

Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.

Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M.

BMC Cancer. 2014 Sep 23;14:696. doi: 10.1186/1471-2407-14-696.

15.

Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.

Tuppurainen L, Sallinen H, Kokki E, Koponen J, Anttila M, Pulkkinen K, Heikura T, Toivanen P, Hämäläinen K, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S.

Hum Gene Ther Clin Dev. 2013 Mar;24(1):29-37. doi: 10.1089/humc.2013.006. Epub 2013 Apr 3.

PMID:
23692381
16.

Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.

Sopo M, Anttila M, Sallinen H, Tuppurainen L, Laurema A, Laidinen S, Hamalainen K, Tuunanen P, Koponen JK, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S.

Int J Cancer. 2012 Nov 15;131(10):2394-401. doi: 10.1002/ijc.27495. Epub 2012 Mar 27.

17.

Preoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancer.

Sallinen H, Heikura T, Laidinen S, Kosma VM, Heinonen S, Ylä-Herttuala S, Anttila M.

Int J Gynecol Cancer. 2010 Dec;20(9):1498-505. doi: 10.1111/IGC.0b013e3181f936e3.

PMID:
21119365
18.

In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.

Huhtala T, Laakkonen P, Sallinen H, Ylä-Herttuala S, Närvänen A.

Nucl Med Biol. 2010 Nov;37(8):957-64. doi: 10.1016/j.nucmedbio.2010.03.001.

PMID:
21055627
19.

Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.

Sallinen H, Anttila M, Gröhn O, Koponen J, Hämäläinen K, Kholova I, Kosma VM, Heinonen S, Alitalo K, Ylä-Herttuala S.

Cancer Gene Ther. 2011 Feb;18(2):100-9. doi: 10.1038/cgt.2010.56. Epub 2010 Sep 24.

PMID:
20865022
20.

Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S.

Mol Ther. 2009 Feb;17(2):278-84. doi: 10.1038/mt.2008.258. Epub 2008 Dec 2.

Supplemental Content

Loading ...
Support Center